These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38518518)

  • 21. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
    Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
    J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
    Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
    Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
    Singh B; Vande Voort JL; Pazdernik VK; Frye MA; Kung S
    J Affect Disord; 2024 Apr; 351():534-540. PubMed ID: 38302067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
    Chisamore N; Danayan K; Rodrigues NB; Di Vincenzo JD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; McIntyre RS; Rosenblat JD
    J Psychopharmacol; 2023 Aug; 37(8):775-783. PubMed ID: 37194253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
    Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
    J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
    Chen MH; Bai YM; Wu HJ; Li CT; Lin WC; Tsai SJ; Su TP; Tu PC
    J Affect Disord; 2023 Nov; 340():471-475. PubMed ID: 37579883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone.
    Kern DM; Canuso CM; Daly E; Johnson JC; Fu DJ; Doherty T; Blauer-Peterson C; Cepeda MS
    Brain Behav; 2023 Aug; 13(8):e3171. PubMed ID: 37475597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
    Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH
    Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suicidality in treatment resistant depression: perspective for ketamine use.
    Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Słupski J; Włodarczyk A; Górska N; Szarmach J; Szałach ŁP; Wiglusz MS; Krysta K; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):258-260. PubMed ID: 31488737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations.
    Pompili M; Sarli G; Erbuto D; Manfredi G; Comparelli A
    Int Clin Psychopharmacol; 2023 May; 38(3):195-200. PubMed ID: 36630183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
    CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
    Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
    J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series.
    Tham JCW; Do A; Fridfinnson J; Rafizadeh R; Siu JTP; Budd GP; Lam RW
    Int Clin Psychopharmacol; 2022 Sep; 37(5):206-214. PubMed ID: 35695279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Cha DS; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    J Psychiatr Res; 2021 Apr; 136():444-451. PubMed ID: 32948309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Low-Dose Ketamine Infusion on the Positive and Negative Domains of Hopelessness and Suicidal Thoughts.
    Lin WC; Chen MH; Su TP; Li CT; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC
    J Clin Psychiatry; 2024 Jul; 85(3):. PubMed ID: 39028544
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.
    Zheng W; Zhou YL; Wang CY; Lan XF; Ning YP
    J Affect Disord; 2023 Aug; 334():145-151. PubMed ID: 37160235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.